Molendotech - Palintest start commercial roll out

RNS Number : 3392L
Frontier IP Group plc
27 December 2018
 

RNS REACH / RNS

AIM: FIPP

27 December 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Palintest starts commercial roll out of Molendotech bathing water quality test SirenBW

 

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces that Palintest, a subsidiary of FTSE 100 group Halma plc, has started commercial roll out of Siren BW, a rapid water testing kit based on technology developed by portfolio company Molendotech Ltd (the "Company").

 

The commercial roll out will focus on the UK and Ireland initially and include the establishment of a number of demonstrator sites. Currently, it can take more than two days for local authorities and regulators to assess the quality of recreational water because samples must be sent to a laboratory for lengthy and complex analysis.

 

Siren BW can be used on location by moderately-skilled technicians and can produce a result in 20 minutes.

 

Palintest's move follows successful technical evaluation and demonstration during the 2018 bathing water season. The technical demonstration programme has also begun at several iconic Australian locations to accelerate the global roll out of the SirenBW during the southern hemisphere summer.

 

Frontier IP holds a 14.1 per cent stake in Molendotech, a spin out from the University of Plymouth. It was established to commercialise the work of Simon Jackson, Professor of Environment and Human Health at the University's Faculty of Medicine and Dentistry.

 

Further applications are being developed with Palintest to leverage the real-time availability of pathogen risk in water. Molendotech is also working with other commercial partners in food and beverage production. Tests under development include those for detecting pathogens on fresh produce and in the water used to irrigate it.

 

 

Palintest open innovation product manager Ian Leahy said: "It sounds strange to be discussing bathing water quality in the middle of a British winter but the fact is that people want to enjoy safe and high quality bathing water all year round - even on Boxing Day! By combining Palintest's core competence of simplifying water safety validation with Molendotech's technology we can finally deliver a screening tool that matches the behaviour of recreational water users."

 

Molendotech chief executive officer Professor Simon Jackson said: "It is a great achievement for the applications of our research to be commercialized with the launch of the first bathing water testing kit by Palintest that will allow a rapid assessment of bathing water quality. Molendotech researchers are working on further developments of the assay that will have many applications in a range of settings and benefit both industry and the public "

 

Frontier IP Group chief executive officer Neil Crabb said: "We're delighted with the rapid progress the agreement with Palintest is making. It has taken less than 18 months from when Molendotech was first incorporated to the full commercial roll out of the first product based on its novel intellectual property. We are confident the Company will continue to make strong progress."

 

For more SirenBW details, please contact ian.leahy@palintest.com

 

 

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

Amrit Nahal (Equity Sales)


ABout frontier IP Group

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

Frontier IP is the commercialisation partner for the University of Plymouth.

ABOUT THE UNIVERSITY OF PLYMOUTH

 

The University of Plymouth is renowned for high quality, internationally-leading education, research and innovation.

 

With a mission to Advance Knowledge and Transform Lives, Plymouth is a *top 50 research university with clusters of world class research across a wide range of disciplines including marine science and engineering, medicine, robotics and psychology. A twice winner of the Queen's Anniversary Prize for Higher Education, the University of Plymouth continues to grow in stature and reputation.

 

It has a strong track record for teaching and learning excellence and has one of the highest numbers of National Teaching Fellows of any UK university. With 21,000 students, and a further 17,000 studying for a Plymouth degree at partner institutions in the UK and around the world, and over 100,000 alumni pursuing their chosen careers globally, it has a growing global presence.

http://www.plymouth.ac.uk 

* Research Fortnight Research Power League Table 2014.

 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.   Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABLBDDGGDBGIB
UK 100

Latest directors dealings